Pathway candidateNCBI-verifiedprotein-coding

YAP1

Yes1 associated transcriptional regulator

NCBI Gene: 10413 Ensembl GeneCards UniProt: P46937

Pathway candidate — not linked to PFS or PSSD by any record here

YAP1 is in the library because it belongs to the signaling & transcription family. No study, report or commentary in the corpus names it, so a variant in YAP1 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 11 (cell signaling and transcription factors). Encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Transcriptional coactivator YAP1
Function (excerpt): Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The Hippo signaling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 prevents its nuclear translocation, thereby regulating the expression of its target genes. The transcriptional regulation of gene expression requires TEAD transcription factors and modulates cell growth, anchorage-independent growth, and induction of epithelial-mesenchymal transition (EMT).
Subcellular location: Cytoplasm; Nucleus; Cell junction, tight junction; Cell membrane.
Tissue specificity: Increased expression seen in some liver and prostate cancers. Isoforms lacking the transactivation domain found in striatal neurons of patients with Huntington disease (at protein level).
Associated conditions: Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development (COB1).

Source: UniProtKB/Swiss-Prot P46937, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

General signaling/transcription machinery; no direct post-drug-syndrome link established for most members — included for completeness of the panel.

Written for the whole signaling & transcription family, not for YAP1 specifically.

Mentioned in 0 corpus records

No corpus record names YAP1 directly yet. It is in the library because it sits in a pathway the corpus tracks (Signaling & transcription).

Also in cell signaling and transcription factors

All 52 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Transcriptional coactivator YAP1
Function (excerpt): Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The Hippo signaling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 prevents its nuclear translocation, thereby regulating the expression of its target genes. The transcriptional regulation of gene expression requires TEAD transcription factors and modulates cell growth, anchorage-independent growth, and induction of epithelial-mesenchymal transition (EMT).
Subcellular location: Cytoplasm; Nucleus; Cell junction, tight junction; Cell membrane.
Tissue specificity: Increased expression seen in some liver and prostate cancers. Isoforms lacking the transactivation domain found in striatal neurons of patients with Huntington disease (at protein level).
Associated conditions: Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or impaired intellectual development (COB1).